Deciphera Pharmaceuticals, Inc.
DelistedCIK 1654151fmd_0BXPRQMRKEARW3AWMVWK642MA7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2024, 34 periods
Latest annual · FY2023
Millions- Total revenues
- 163
- Gross profit
- 160
- Operating income
- (211)
- Net income
- (195)
- Free cash flow
- (147)
Latest quarter · Q1 FY2024
Millions- Total revenues
- 45
- Gross profit
- 43
- Operating income
- (49)
- Net income
- (45)
- Free cash flow
- (55)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- +57.2%
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
Deciphera Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $163.4 million | $134 million | +21.9% | 10-K 2024-02-07 · proof |
| Gross profit | $159.6 million | $125.3 million | +27.4% | 10-K 2024-02-07 · proof |
| Operating income | -$211 million | -$182.7 million | 10-K 2024-02-07 · proof | |
| Net income | -$194.9 million | -$178.9 million | 10-K 2024-02-07 · proof | |
| Cash from operating activities | -$146.7 million | -$152.9 million | 10-K 2024-02-07 · proof | |
| Free cash flow | -$147.5 million | -$153.7 million | 10-K 2024-02-07 · proof | |
| Total assets | $473.6 million | $454 million | +4.3% | 10-K 2024-02-07 · proof |
| Total liabilities | $122.7 million | $112.3 million | +9.2% | 10-K 2024-02-07 · proof |
| Cash and cash equivalents | $83.5 million | $64.7 million | +29% | 10-K 2024-02-07 · proof |
- What was Deciphera Pharmaceuticals, Inc.'s revenue in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported revenue of $163.4 million for fiscal 2023 (the year ended Dec 31, 2023), against $134 million the year before (+21.9%). Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What was Deciphera Pharmaceuticals, Inc.'s gross profit in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported gross profit of $159.6 million for fiscal 2023 (the year ended Dec 31, 2023), against $125.3 million the year before (+27.4%). Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What was Deciphera Pharmaceuticals, Inc.'s operating income in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported operating income of -$211 million for fiscal 2023 (the year ended Dec 31, 2023), against -$182.7 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What was Deciphera Pharmaceuticals, Inc.'s net income in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported net income of -$194.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$178.9 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What was Deciphera Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported cash from operating activities of -$146.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$152.9 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What was Deciphera Pharmaceuticals, Inc.'s free cash flow in fiscal 2023?
- Deciphera Pharmaceuticals, Inc. reported free cash flow of -$147.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$153.7 million the year before. Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What are Deciphera Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2023, Deciphera Pharmaceuticals, Inc. reported total assets of $473.6 million, against $454 million a year earlier (+4.3%). Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What are Deciphera Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2023, Deciphera Pharmaceuticals, Inc. reported total liabilities of $122.7 million, against $112.3 million a year earlier (+9.2%). Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
- What are Deciphera Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Deciphera Pharmaceuticals, Inc. reported cash and cash equivalents of $83.5 million, against $64.7 million a year earlier (+29%). Source: the 10-K filed with the SEC on Feb 7, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1654151&period_type=annual&limit=5"Information only, not investment advice.